Evidence map›Paper›PMID 33320347›Full record

ArticleCancer2021

Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.

Julie O Culver, Charité N Ricker, Joseph Bonner, John Kidd, Duveen Sturgeon, Rachel Hodan, Kerry Kingham, Katrina Lowstuter, Nicolette M Chun, Alexandra P Lebensohn and 15 more

Abstract read
In one paragraph

Article in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. A scalable new model of germline cancer genomic care delivery: Assessing psychological outcomes.Genetics in medicine : official journal of the American College of Medical Genetics · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Julie O CulverUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.ORCID 0000-0001-8658-3507
Charité N RickerUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Joseph BonnerCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
John KiddMyriad Genetics, Salt Lake City, Utah.
Duveen SturgeonCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
Rachel HodanStanford University School of Medicine, Stanford, California.ORCID 0000-0003-2887-4079
Kerry KinghamStanford University School of Medicine, Stanford, California.
Katrina LowstuterUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Nicolette M ChunStanford University School of Medicine, Stanford, California.
Alexandra P LebensohnStanford University School of Medicine, Stanford, California.
Courtney Rowe-TeeterStanford University School of Medicine, Stanford, California.
Peter LevonianStanford University School of Medicine, Stanford, California.
Katlyn PartynskiUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Karlena Lara-OteroStanford University School of Medicine, Stanford, California.
Christine HongCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
Jennifer Morales PichardoCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
Meredith A MillsStanford University School of Medicine, Stanford, California.ORCID 0000-0003-0665-8797
Krystal BrownMyriad Genetics, Salt Lake City, Utah.
Caryn LermanUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Uri LadabaumStanford University School of Medicine, Stanford, California.
Kevin J McDonnellCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
James M FordStanford University School of Medicine, Stanford, California.ORCID 0000-0002-2513-7025
Stephen B GruberCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
Allison W KurianStanford University School of Medicine, Stanford, California.ORCID 0000-0002-6175-9470
Gregory E IdosCenter for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4M
Southern California Clinical and Translational Science InstituteUL1TR001855 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Thomas A Buchanan, Michele D. Kipke · 2016 to 2026
$81.3M
Neuroscience-based Interventions for Cancer Risk Behavior ChangeR35CA197461 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LERMAN, CARYN · 2015 to 2021
$6.0M
The Epidemiology of Immune Responses in Colorectal CancerR01CA197350 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2015 to 2019
$3.2M
Southern California Clinical and Translational Science InstituteKL2TR000131 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2012 to 2015
$2.1M
Anton B. Burg FoundationDaniel and Maryann FongMyriad Genetics HCP-005NCATS NIH HHS KL2 TR000131NCATS NIH HHS UL1 TR001855NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA14089NCI NIH HHS R01 CA197350NCI NIH HHS R35 CA197461NIH HHS KL2 TR000131
6 · The paper itself

Abstract

backgroundLittle is known about the psychological outcomes of germline multigene panel testing, particularly among diverse patients and those with moderate-risk pathogenic variants (PVs).

methodsStudy participants (N = 1264) were counseled and tested with a 25- or 28-gene panel and completed a 3-month postresult survey including the Multidimensional Impact of Cancer Risk Assessment (MICRA).

resultsThe mean age was 52 years, 80% were female, and 70% had cancer; 45% were non-Hispanic White, 37% were Hispanic, 10% were Asian, 3% were Black, and 5% had another race/ethnicity. Approximately 28% had a high school education or less, and 23% were non-English-speaking. The genetic test results were as follows: 7% had a high-risk PV, 6% had a moderate-risk PV, 35% had a variant of uncertain significance (VUS), and 52% were negative. Most participants (92%) had a total MICRA score ≤ 38, which corresponded to a mean response of "never," "rarely," or only "sometimes" reacting negatively to results. A multivariate analysis found that mean total MICRA scores were significantly higher (more uncertainty/distress) among high- and moderate-risk PV carriers (29.7 and 24.8, respectively) than those with a VUS or negative results (17.4 and 16.1, respectively). Having cancer or less education was associated with a significantly higher total MICRA score; race/ethnicity was not associated with the total MICRA score. High- and moderate-risk PV carriers did not differ significantly from one another in the total MICRA score, uncertainty, distress, or positive experiences.

conclusionsIn a diverse population undergoing genetic counseling and multigene panel testing for hereditary cancer risk, the psychological response corresponded to test results and showed low distress and uncertainty. Further studies are needed to assess patient understanding and subsequent cancer screening among patients from diverse backgrounds. LAY SUMMARY: Multigene panel tests for hereditary cancer have become widespread despite concerns about adverse psychological reactions among carriers of moderate-risk pathogenic variants (mutations) and among carriers of variants of uncertain significance. This large study of an ethnically and economically diverse cohort of patients undergoing panel testing found that 92% "never," "rarely," or only "sometimes" reacted negatively to results. Somewhat higher uncertainty and distress were identified among carriers of high- and moderate-risk pathogenic variants, and lower levels were identified among those with a variant of uncertain significance or a negative result. Although the psychological response corresponded to risk, reactions to testing were favorable, regardless of results.

Indexed as

Germ CellsAdolescentAdultAgedAged, 80 and overAsian PeopleBlack PeopleCohort StudiesFemaleGenetic Carrier ScreeningGenetic CounselingGenetic TestingHispanic or LatinoHumansMaleMiddle Agedgenetic counselinggenetic techniquesgenetic testinghereditary neoplastic syndromespsycho-oncologypsychosocial factors

Identifiers

PMID33320347
PMCPMC8058169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.